Overview

  • Product name

    Ki20227, c-Fms tyrosine kinase inhibitor
  • Description

    Potent, selective c-Fms tyrosine kinase inhibitor
  • Biological description

    Potent, selective c-Fms tyrosine kinase inhibitor (IC50 values are 2, 12, 217 and 451 nM for c-Fms, VEGFR-2, PDGFRβ and c-Kit respectively). Suppresses osteoclast differentiation and osteolysis. Shows antimetastatic effects in vivo.
  • Purity

    > 95%
  • CAS Number

    623142-96-1
  • Chemical structure

    Chemical Structure

Properties

References

This product has been referenced in:

  • Toy EP  et al. Inhibition of the c-fms proto-oncogene autocrine loop and tumor phenotype in glucocorticoid stimulated human breast carcinoma cells. Breast Cancer Res Treat 129:411-9 (2011). Read more (PubMed: 21063905) »
  • Hiraga T & Nakamura H Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals. Int J Cancer 124:215-22 (2009). Read more (PubMed: 18814279) »
  • Uemura Y  et al. The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis. J Neuroimmunol 195:73-80 (2008). Read more (PubMed: 18378004) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab141357.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up